Early versus late JAK-STAT–IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.aec4107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Camila Macedo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Janus Kinases, Signal Transduction, Graft Rejection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Subclinical rejection after liver transplantation precludes immunosuppression withdrawal despite normal clinical function. To better understand the immunobiology of early subclinical rejection, we performed longitudinal, multimodal immune profiling and single-cell RNA sequencing (scRNA-seq) in adult living-donor recipients ( n = 13) participating in an interventional immunosuppression withdrawal trial. Samples from patients with subclinical rejection (termed “nonpermissive”) at 12 months posttransplant exhibited distinct immune trajectories from those with quiescent (“permissive”) allografts despite comparable baseline profiles. Central to these distinct dynamics was biphasic Janus kinase (JAK)–signal transducer and activator of transcription (STAT)–interferon signaling. Greater interferon-stimulated gene (ISG) expression and JAK-STAT activation occurred postreperfusion in permissive allograft recipients, which reversed at 12 months, when elevated ISG expression and JAK-STAT signaling were evident in nonpermissive recipients exhibiting subclinical rejection. We then leveraged our findings to ascertain whether a comparable signature existed in internal and external bulk RNA-seq and scRNA-seq liver transplant cohorts. Across cohorts, including a rodent model, there was a similar elevation in JAK-STAT signaling in instances of allograft rejection. We also detected distinct, portal-based phosphorylated STAT1 staining in a preliminary analysis of biopsies exhibiting histologic rejection compared with nonrejecting controls. Moreover, ruxolitinib-mediated JAK inhibition suppressed alloreactive CD8 + T cell proliferation and inflammatory-mediator production in vitro. Together, these exploratory findings suggest a temporal, biphasic role for JAK-STAT signaling in the regulation and occurrence of T cell–mediated rejection after liver transplant and highlight JAK inhibition as a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
- Cancer Bioinformatics Services, Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
- Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, NY 10032, USA.
- Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN 47405, USA.
- Organ Pathobiology and Therapeutics Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
ORCID-Profile: Camila Macedo, Yannis Hadjiyannis, Beth D Elinoff, Ibrahim M Abukhiran, Aatur D Singhi, Brian Isett, Kevin Breen, Alan F Zahorchak, Erin M Ables, Jia-Jun Liu, Silvia Liu, Megan Sykes, Adriana Zeevi, Douglas Landsittel, Fadi G Lakkis, Abhinav Humar, Diana M Metes, Angus W Thomson
Förderung
- NIAID NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- National Cancer Institute
- Burroughs Wellcome Fund
- Pittsburgh Liver Research Center, University of Pittsburgh
- University of Pittsburgh Medical Center
Zitieren
APA
Macedo, C., Hadjiyannis, Y., Tran, L. M., Elinoff, B. D., Abukhiran, I. M., Singhi, A. D., Isett, B., Breen, K., Zahorchak, A. F., Ables, E. M., Liu, J. J., Liu, S., Sykes, M., Zeevi, A., Landsittel, D., Lakkis, F. G., Humar, A., Metes, D. M., & Thomson, A. W. (2026). Early versus late JAK-STAT–IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aec4107
Vancouver
Macedo C, Hadjiyannis Y, Tran LM, Elinoff BD, Abukhiran IM, Singhi AD, et al. Early versus late JAK-STAT–IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aec4107
BibTeX
@article{Macedo2026,
author = {Macedo, Camila and Hadjiyannis, Yannis and Tran, Lillian M and Elinoff, Beth D and Abukhiran, Ibrahim M and Singhi, Aatur D and Isett, Brian and Breen, Kevin and Zahorchak, Alan F and Ables, Erin M and Liu, Jia-Jun and Liu, Silvia and Sykes, Megan and Zeevi, Adriana and Landsittel, Douglas and Lakkis, Fadi G and Humar, Abhinav and Metes, Diana M and Thomson, Angus W},
title = {Early versus late JAK-STAT–IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.aec4107}
}
EUVIMED